drugset / Trial / NCT03441516

Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia

NCT03441516

Phase 4 Unknown 79 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the performance of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) in patients with Alzheimer's disease (AD).

Timeline

Start
2018-04-19
Primary completion
2019-07-04
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Choline Alfoscerate Unknown 400 mg Oral
Comparator Donepezil Small molecule 10 mg Oral

Indications